This is the authors' abstract. We don't add key points for this paper.
This study investigated the optimization of extraction conditions for formulating oil-in-water (O/W) emulsions to encapsulate ashwagandha, with a focus on enhanced antioxidant activity and glucose-modulatory potential. The Box-Behnken design using response surface methodology was employed to evaluate four independent variables with different levels, including stirring time (10-30 min), temperature (40-60°C), ultrasonication power (50-90%), and ashwagandha to oil ratio (1-10% (w/w)). The extract prepared with optimized extraction conditions was used to formulate O/W emulsions with varying concentrations of decaglycerol monolaurate (5, 7, and 10% (w/w)) as a hydrophilic emulsifier. The fitted models generated for all responses were statistically significant ( p < 0.05) with a non-significant lack of fit ( p > 0.05). The TPC ranged from 53.76 to 146.28 mg GAE/g, TFC ranged from 3.96 to 85.83 mg QE/g, DPPH ranged from 20.93 to 74.17%, FRAP ranged from 53.49 to 172.49 mg TE/g, and ABTS ranged from 34.51% to 108.63%. Optimization of these extraction parameters yields the optimal conditions: 24 min of stirring, 45°C, 90% ultrasonication power, and a 10% (w/w) ashwagandha-to-oil ratio. Furthermore, in subsequent biological evaluation, the optimized extract demonstrated significant in vitro enzyme inhibition, with 77% α-amylase and 67.7% α-glucosidase inhibition, suggesting its carbohydrate-hydrolyzing modulation potential. The 7% (w/w) decaglycerol monolaurate was identified as optimal for superior stability and significant biological activity. The volume mean diameter ( d 4,3 ) was 0.6 μm with a span factor of 0.598, indicating a uniform and stable droplet distribution. Further testing confirmed that the O/W emulsions remained stable across various pH levels with no phase separation. It remained sensitive to salt stress and showed significant time-dependent degradation during the 30-day storage study. These findings provide valuable information in designing nutritional products aimed at glucose modulation.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: